Natural Autoantibody Application in IVIg
As a fundamental part of the immune system, natural autoantibodies (NAA) have a wide range of clinical applications including intravenous immunoglobulin. Creative Biolabs is committing to the researches of natural autoantibodies and related diseases based on our abundant experience, advanced technology platform, and professional teams. Our objective is to provide the best and most professional solutions and services available to our customers throughout the world.
Background
What Is Intravenous Immunoglobulin?
Intravenous immunoglobulin (IVIg) is a product made up of immunoglobulin or antibodies that can be given intravenously through a vein. It is one of the immunoglobulin therapies that use a mixture of normal human antibodies to treat a number of related diseases, particular immunologic deficiency. IVIg can be liquid or lyophilized powder containing human G isotype immunoglobulins (Ig) which is usually prepared from the human healthy blood.
- Composition: IVIg approximately contains exclusively intact IgG which is similar to that of normal human serum.
- Differences: all IVIg are not perfectly similar due to multiple donors and the small intervariability in the process of production.
- Mechanisms: IVIg infusions can supplement antibodies and stimulate or modulate the adaptive immune response.
- Side effects: rare side effects of IVIg include allergic reactions, pain, hemolysis, hemolytic anemia, thrombosis, acute renal failure, hypokalemic nephropathy, etc.
Fig.1 Schematic representation of proposed mechanisms of action of IVIg in autoimmune and inflammatory diseases. (Negi, 2007)
NAA & IVIg
NAA and Intravenous Immunoglobulin
Natural autoantibodies are a type of antibodies produced by the human immune system, which suggests that NAA are a composition of human antibodies also IVIg. At the same time, IVIg has been applied to the treatment with a variety of NAA-related diseases especially autoimmune and systemic inflammatory conditions. Increasing researches indicated that IVIg could selectively and significantly reduce levels of abnormal antibodies without decreasing the levels of normal antibodies in some diseases. It was considered that IVIg can reverse abnormal NAA by increasing the catabolism of all serum IgG antibodies which finally replaced the abnormal NAA.
Scientific research and clinical usage show that IVIg is the first treatment achieving the perfect therapeutic effect in NAA-related diseases through selectively decreasing the circulating pathogenic NAA without affecting the level of normal antibodies.
Fig.2 The impact of IVIG on the innate and adaptive immune compartments in the context of autoimmune and inflammatory diseases. (Galeotti, 2017)
FAQs
-
Q: What role does IVIg play in the treatment of NAA-related diseases?
A: IVIg treatment, which includes human antibodies, can selectively decrease abnormal antibodies in NAA-related diseases without impacting normal antibodies. -
Q: How does Creative Biolabs contribute to the research and application of natural autoantibodies (NAA)?
A: Creative Biolabs utilizes its advanced technology and professional experience in biology to provide comprehensive solutions and services, focusing on natural autoantibodies and related applications including intravenous immunoglobulin.
Our Service
NAA-related Applications Studied by Creative Biolabs
NAA is acting more and more important role in the immune system, human diseases, and clinical therapies. With the development of modern biological technologies, NAA has been widely used for intravenous immunoglobulin, clinical diagnosis, vaccine development, tumor surveillance, and other applications. As a leader in the biology industry, Creative Biolabs has been committed to the natural autoantibodies and related applications for several years. We are capable to provide our customers with a full range of quality services based on our powerful platform.
If you are interested in the natural autoantibodies and related applications or you have any question, just feel free to contact us for more detailed information.
Resource
Reference
- Negi, V.S.; et al. Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action. Journal of Clinical Immunology. 2007, 27(3): 233-245.
- Galeotti, C.; et al. IVIG-mediated effector functions in autoimmune and inflammatory diseases. International Immunology. 2017, 29(11): 491-498.